All Trials

A Phase 2 Trial of Intraoperative Fluorescent Angiography to Decrease Pharyngocutaneous Fistula Rates in Patients Undergoing Hypopharyngeal Reconstruction

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with previously irradiated stage II–IV laryngeal or hypopharyngeal squamous cell carcinoma undergoing salvage total laryngectomy receive intraoperative indocyanine green (ICG) fluorescence angiography with the SPY system to assess mucosal perfusion, with resection of hypoperfused tissue prior to reconstruction. ICG is a near-infrared fluorescent dye used for real-time perfusion imaging, aiming to reduce postoperative pharyngocutaneous fistula, particularly in intraoperatively defined high-risk cases.

ClinicalTrials.gov ID: NCT06831149

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with suspected or confirmed stage IIIC–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive laparotomy (BLOODS ≥2, Hgb ≥10 g/dL) are randomized to intraoperative acute normovolemic hemodilution (autologous whole-blood collection with crystalloid/colloid replacement and reinfusion) versus standard intraoperative care. The trial tests whether ANH reduces perioperative allogeneic red blood cell transfusion within 30 days.

ClinicalTrials.gov ID: NCT06290193

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum-refractory or -resistant epithelial ovarian cancer (including carcinosarcoma), ECOG 0–2, receive autologous B7‑H3 (CD276)–targeted CAR T cells after lymphodepletion, administered either intraperitoneally for peritoneal-only disease or intravenously if extra-peritoneal or IP not feasible. Investigational therapy targets broadly overexpressed B7‑H3; trial assesses feasibility/safety with dose escalation and early response signals.

ClinicalTrials.gov ID: NCT06646627

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with measurable high-grade serous ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior lines (platinum-sensitive and -resistant cohorts; ECOG 0–1), excluding significant ILD/pneumonitis and other key comorbidities. Investigational CDH6-targeting antibody-drug conjugate raludotatug deruxtecan (anti-CDH6–DXd topoisomerase I payload) is combined with either carboplatin, paclitaxel, or bevacizumab, with chemotherapy for up to six cycles and continued R-DXd until progression.

ClinicalTrials.gov ID: NCT06843447

Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–2) receive oral CPI-0209 (tulmimetostat), a dual EZH2/EZH1 inhibitor aiming to reverse epigenetic platinum resistance, combined with carboplatin followed by CPI-0209 maintenance. Prior bevacizumab or PARP inhibitor is allowed; excludes platinum-resistant disease and significant comorbidities.

ClinicalTrials.gov ID: NCT05942300

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors—emphasizing platinum‑refractory/resistant ovarian cancer—who have exhausted standard therapy receive CUSP06 (AMT‑707), a cadherin‑6–targeted IgG1 antibody‑drug conjugate delivering an exatecan (topoisomerase‑I) payload, given IV every 21 days. Open‑label dose escalation with tumor‑specific expansions; key exclusions include prior topoisomerase‑I ADCs and active CNS disease.

ClinicalTrials.gov ID: NCT06234423

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (relapse ≤6 months after last platinum; ≤2 prior cytotoxic lines) receive carboplatin/paclitaxel plus oral defactinib, a reversible ATP-competitive FAK/Pyk2 inhibitor aimed at re-sensitizing to platinum. Primary aims are safety/tolerability and objective response by RECIST 1.1.

ClinicalTrials.gov ID: NCT03287271

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with high-risk NMIBC (CIS ± Ta/T1; includes BCG-unresponsive/exposed and those unfit for or declining cystectomy) receive intravesical PF-08052667 as monotherapy or combined with BCG and/or subcutaneous sasanlimab (anti–PD-1), with dose escalation/expansion to assess safety, PK, and preliminary antitumor activity. The molecular target of PF-08052667 has not been disclosed.

ClinicalTrials.gov ID: NCT07206225

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic HER2-expressing solid tumors (HER2-positive or HER2-low), including breast and gastric/GEJ cancers after standard therapies, receive IKS014, a HER2-targeting antibody–drug conjugate using a trastuzumab backbone linked to the microtubule inhibitor MMAF. Open-label dose escalation/expansion treats in 21-day cycles until progression to establish RP2D and assess antitumor activity.

ClinicalTrials.gov ID: NCT05872295

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with metastatic HR-positive, HER2-negative/low breast cancer receive STEMVAC, an intradermal multi-antigen plasmid DNA vaccine (targets CD105, YB-1, SOX2, CDH3, MDM2; GM-CSF–adjuvanted to elicit T-cell responses against cancer stem cell–associated proteins), added to either ongoing endocrine therapy plus a CDK4/6 inhibitor (first/second line) or to capecitabine after progression on endocrine therapy. Suitable for ECOG 0–1 patients with measurable disease; includes serial biopsies and immunologic monitoring.

ClinicalTrials.gov ID: NCT07112053